CAS 1643913-93-2

Padnarsertib

CAS: 1643913-93-2

(E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(4,4-difluoropiperidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide

Fórmula: C₃₅H₂₉F₃N₄O₃

Pureza: 98%

Peso molecular: 610.63

Ref: IN-DG630415

KPT9274

CAS: 1643913-93-2

KPT9274

Fórmula: C₃₅H₂₉F₃N₄O₃

Pureza: ≥98%, 10 mM in DMSO

Peso molecular: 610.62

Ref: 54-BUP05419

2-​Propenamide, 3-​(6-​amino-​3-​pyridinyl)​-​N-​[[5-​[4-​[(4,​4-​difluoro-​1-​piperidinyl)​carbonyl]​phenyl]​-​7-​(4-​fluorophenyl)​-​2-​benzofuranyl]​methyl]​-​, (2E)​-

CAS: 1643913-93-2

Fórmula: C₃₅H₂₉F₃N₄O₃

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 610.6250

Ref: IN-DA001UUS

KPT 9274 (ATG-019)

CAS: 1643913-93-2

Fórmula: C₃₅H₂₉F₃N₄O₃

Peso molecular: 610.64

Ref: 4Z-K-031074

KPT9274

CAS: 1643913-93-2

KPT9274 (PAK4-IN-1) is a non-competitive dual inhibitor of PAK4 and NAMPT(IC50= ~120 nM). It is an orally bioavailable small molecule.

Fórmula: C₃₅H₂₉F₃N₄O₃

Pureza: 99.75% - 99.93%

Cor e Forma: Solid

Peso molecular: 610.62

Ref: TM-T4354

KPT 9274

CAS: 1643913-93-2

KPT 9274 is a molecule that binds to the citric acid cycle effector protein, β-catenin. It has minimal toxicity and is energy-independent. KPT 9274 blocks ATP production by binding to the death protein and inhibits atp production. KPT 9274 has been shown to be effective against high-risk disease such as acute myeloid leukemia (AML). The pharmacokinetic properties of KPT 9274 have been studied in vivo using a rat model. This drug is metabolized by fatty acid oxidation and glucuronidation in the liver and excreted in bile.

Fórmula: C₃₅H₂₉F₃N₄O₃

Pureza: Min. 95%

Peso molecular: 610.63 g/mol

Ref: 3D-FA103866